Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.13
-1.08 (-13.15%)
At close: Jun 26, 2026, 4:00 PM EDT
7.36
+0.23 (3.29%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Company Description
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
The company was incorporated in 2016 and is headquartered in Mountain View, California.
Unicycive Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Shalabh Gupta |
Contact Details
Address: 1975 West El Camino Real, Suite 204 Mountain View, California 94040 United States | |
| Phone | 650 351 4495 |
| Website | unicycive.com |
Stock Details
| Ticker Symbol | UNCY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001766140 |
| CUSIP Number | 90466Y202 |
| ISIN Number | US90466Y2028 |
| Employer ID | 81-3638692 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pramod Gupta Ph.D. | Executive Vice President of Pharmaceutical and Business Operations |
| Douglas Jermasek M.B.A. | Executive Vice President of Corporate Strategy |
| John W. Townsend CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 15, 2026 | EFFECT | Notice of Effectiveness |
| Jun 5, 2026 | 8-K | Current Report |
| Jun 5, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 30, 2026 | ARS | Filing |